Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLife Solutions SEC filings document material-event disclosures for a Nasdaq-listed life sciences supplier focused on cell processing tools and services for cell and gene therapy. Recent 8-K filings cover unaudited financial results, continuing-operations performance, operational highlights, and Regulation FD investor presentations describing the company’s bioproduction products and CGT market focus.
The filing record also includes governance and corporate-administration disclosures, including stockholder voting results from the annual meeting, director elections, advisory executive compensation votes, auditor ratification, and an officer retirement notice. These filings frame the company’s public reporting around operating results, product-market disclosures, governance matters, and executive-level changes.
BioLife Solutions (BLFS) reported an insider transaction on Form 4. Director Joydeep Goswami sold 1,666 shares of Common Stock on 10/24/2025 at a price of $28.99 per share, coded as an open-market sale (S). The transaction was executed under a Rule 10b5-1(c) trading plan effective 12/13/2024. Following this sale, Goswami beneficially owns 44,986 shares, held directly.
BioLife Solutions (BLFS) reported an insider transaction by its President & CEO and Director. On October 22, 2025, the reporting person sold 37,795 shares of common stock at $27.3 per share under a Rule 10b5-1(c) trading plan. Following the sale, the reporting person beneficially owns 489,998 shares, held directly.
The filing notes the 10b5-1 plan was effective October 19, 2023 and was adopted to satisfy tax withholding obligations related to the vesting of restricted stock.
BioLife Solutions (BLFS) filed a Form 4 indicating CTO Sean Werner sold 275 shares of common stock at $27.82 on October 20, 2025. The filing states the trade was executed under a Rule 10b5-1(c) plan adopted effective 07-17-2024 to satisfy tax withholding related to restricted stock vesting. Following the transaction, Werner beneficially owned 26,037 shares, held directly.
BioLife Solutions (BLFS) director Joydeep Goswami reported an open-market sale of 1,334 shares of common stock on 10/16/2025. The transaction was executed at a weighted average price with trade prices ranging from $28.99 to $29.00.
Following the sale, the reporting person beneficially owns 46,652 shares directly. The filing states the trades were made under a Rule 10b5-1(c) trading plan adopted effective 12/13/2024.
BioLife Solutions (BLFS): Casdin Partners Master Fund reported an open‑market sale of 750,000 shares of common stock on 10/15/2025 at a weighted average price of $28.5471, executed in multiple trades within the $28.50–$28.8354 range. After the transactions, 5,957,165 shares were beneficially owned indirectly. The shares are held directly by the Master Fund and may be deemed to be indirectly beneficially owned by Casdin Capital, Casdin Partners GP, and Eli Casdin.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Financial Officer. On 10/09/2025, the CFO executed a sale of 833 shares of common stock at a price of $27.36 per share. Following this transaction, the officer beneficially owns 183,353 shares, held directly.
The filing notes the sale was made pursuant to a Rule 10b5-1(c) trading plan, effective 01/03/2023, to satisfy tax withholding obligations arising from the vesting of restricted stock. This indicates a pre-established, automated plan tied to equity award taxation rather than a discretionary open‑market trade.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Marketing Officer. On October 9, 2025, the officer sold 289 shares of common stock at $27.36 per share. Following the sale, the officer beneficially owned 133,617 shares, held directly. The filing notes the sale was made under a Rule 10b5-1(c) trading plan effective January 3, 2023, established to satisfy tax withholding obligations related to the vesting of restricted stock.
BioLife Solutions (BLFS) insider transaction: EVP & Chief Scientific Officer Aby J. Mathew reported selling 509 shares of common stock at $27.36 on October 9, 2025. The filing states the sale was made under a Rule 10b5-1(c) trading plan effective January 3, 2023, to cover tax withholding tied to restricted stock vesting. After the transaction, he beneficially owns 350,912 shares, held directly. The report was filed by one reporting person.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Human Resources Officer, Sarah Aebersold. On 10/09/2025, she sold 188 shares of common stock at $27.36 per share and now beneficially owns 77,169 shares, held directly. The filing states the sale was executed under a Rule 10b5-1(c) trading plan, effective 01/03/2023, to satisfy tax withholding obligations tied to the vesting of restricted stock.
BioLife Solutions (BLFS) reported an insider transaction by its Chief Quality and Operations officer. On 10/09/2025, the reporting person sold 419 shares of common stock at $27.36 per share in a transaction coded “S.” The filing states this sale was made under a Rule 10b5-1(c) trading plan adopted effective 01-03-2023 to satisfy tax withholding obligations upon the vesting of restricted stock.
Following the sale, the reporting person beneficially owned 193,253 shares, held directly.